@article{SCI21768,
author = {Laura Riboni},
title = {Cross-talk between tumor stem cells and tumor cells: a glioblastoma strategy to promote malignancy},
journal = {Stem Cell Investigation},
volume = {5},
number = {0},
year = {2018},
keywords = {},
abstract = {Glioblastoma multiforme (GBM) is the most frequent and malignant type of primary tumors of the central nervous system. Despite current advances in multimodal therapies, involving advanced surgery, radio- and chemotherapy, and the development of innovative targeted therapies the outcome for patients with GBM is nearly always fatal, with a median survival time of only 12–15 months (1). Various obstacles hamper development of effective therapies, including cellular and molecular heterogeneity, high proliferation rate, pervasive tumor cell infiltration, intensive angiogenesis, therapeutic resistance, and, not last, the lack of a full understanding of the pathobiology of the disease.},
issn = {2313-0792}, url = {https://sci.amegroups.org/article/view/21768}
}